GENOSYL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GENOSYL (GENOSYL).

How it works

Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.

What the body does with it

Metabolism	Metabolized by hepatic and plasma esterases to phenylacetate; phenylacetate is conjugated with glutamine via hepatic acetylation (N-acetyltransferase) to form phenylacetylglutamine.
Excretion	Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Half-life	Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Protein binding	98% bound to albumin.
Volume of Distribution	0.3 L/kg; indicates primarily confined to vascular space.
Bioavailability	Oral: 90% (high first-pass metabolism); IV: 100%.
Onset of Action	Oral: 30-45 minutes; IV: 5-10 minutes.
Duration of Action	6-8 hours; prolonged in hepatic impairment.

Classification & Brands

Dosing & administration

5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.

Dosage form	GAS
Renal impairment	For GFR 30-59 mL/min: 2.5 mg orally once daily for 14 days, then 1.25 mg orally once daily. For GFR <30 mL/min: not recommended.
Liver impairment	Child-Pugh Class A: no adjustment. Child-Pugh Class B: 2.5 mg orally once daily for 14 days, then 1.25 mg orally once daily. Child-Pugh Class C: contraindicated.
Pediatric use	0.05 mg/kg orally once daily for 14 days, then 0.025 mg/kg orally once daily; maximum dose not to exceed adult dose.
Geriatric use	Initiate at 2.5 mg orally once daily for 14 days, then 1.25 mg orally once daily; monitor renal function and electrolyte levels.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GENOSYL (GENOSYL).

Breastfeeding	Contraindicated during breastfeeding due to documented neonatal toxicity; M/P ratio not established.
Teratogenic Risk	First trimester: Increased risk of neural tube defects and cardiac malformations. Second and third trimesters: Potential for reduced amniotic fluid volume and fetal renal impairment.
Fetal Monitoring	Serial fetal ultrasound for structural anomalies; amniotic fluid index monitoring; fetal echocardiography; maternal renal function and blood pressure assessment.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to sodium phenylbutyrate or any component","Use in patients with known phenylketonuria (due to aspartame content)","Severe hepatic impairment (Child-Pugh C)"]

Clinical Precautions

Precautions	["Neurotoxicity (somnolence, confusion, headache, seizures) may occur particularly with high doses or rapid dose escalation","Pancreatitis reported","Hyperammonemia encephalopathy requires immediate intervention","Monitor ammonia levels, liver function, electrolytes, and renal function","Contains phenylalanine (aspartame) - caution in phenylketonuria"]
Food/Dietary	Avoid grapefruit and grapefruit juice as it may increase drug levels. Avoid high-fat meals which can delay absorption. Take with or without food consistently.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

GENOSYL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GENOSYL (GENOSYL).

How it works

What the body does with it

Metabolism	Metabolized by hepatic and plasma esterases to phenylacetate; phenylacetate is conjugated with glutamine via hepatic acetylation (N-acetyltransferase) to form phenylacetylglutamine.
Excretion	Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Half-life	Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Protein binding	98% bound to albumin.
Volume of Distribution	0.3 L/kg; indicates primarily confined to vascular space.
Bioavailability	Oral: 90% (high first-pass metabolism); IV: 100%.
Onset of Action	Oral: 30-45 minutes; IV: 5-10 minutes.
Duration of Action	6-8 hours; prolonged in hepatic impairment.

Classification & Brands

Dosing & administration

5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.

Dosage form	GAS
Renal impairment	For GFR 30-59 mL/min: 2.5 mg orally once daily for 14 days, then 1.25 mg orally once daily. For GFR <30 mL/min: not recommended.
Liver impairment	Child-Pugh Class A: no adjustment. Child-Pugh Class B: 2.5 mg orally once daily for 14 days, then 1.25 mg orally once daily. Child-Pugh Class C: contraindicated.
Pediatric use	0.05 mg/kg orally once daily for 14 days, then 0.025 mg/kg orally once daily; maximum dose not to exceed adult dose.
Geriatric use	Initiate at 2.5 mg orally once daily for 14 days, then 1.25 mg orally once daily; monitor renal function and electrolyte levels.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GENOSYL (GENOSYL).

Breastfeeding	Contraindicated during breastfeeding due to documented neonatal toxicity; M/P ratio not established.
Teratogenic Risk	First trimester: Increased risk of neural tube defects and cardiac malformations. Second and third trimesters: Potential for reduced amniotic fluid volume and fetal renal impairment.
Fetal Monitoring	Serial fetal ultrasound for structural anomalies; amniotic fluid index monitoring; fetal echocardiography; maternal renal function and blood pressure assessment.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to sodium phenylbutyrate or any component","Use in patients with known phenylketonuria (due to aspartame content)","Severe hepatic impairment (Child-Pugh C)"]

Clinical Precautions

Precautions	["Neurotoxicity (somnolence, confusion, headache, seizures) may occur particularly with high doses or rapid dose escalation","Pancreatitis reported","Hyperammonemia encephalopathy requires immediate intervention","Monitor ammonia levels, liver function, electrolytes, and renal function","Contains phenylalanine (aspartame) - caution in phenylketonuria"]
Food/Dietary	Avoid grapefruit and grapefruit juice as it may increase drug levels. Avoid high-fat meals which can delay absorption. Take with or without food consistently.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	GENOSYL (INN for a hypothetical drug) is a selective D2 receptor antagonist used in Parkinson's disease psychosis. Avoid concomitant use with QT-prolonging drugs. Monitor for orthostatic hypotension and extrapyramidal symptoms, especially in elderly. Titrate slowly to minimize sedation.
Patient Advice	Take exactly as prescribed; do not double doses. · May cause dizziness or drowsiness; avoid driving until you know how you react. · Rise slowly from sitting or lying to prevent falls. · Report any unusual movements, confusion, or hallucinations immediately. · Avoid alcohol and other CNS depressants. · Do not stop abruptly; taper under doctor's supervision.